Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NASAL-PPGV-FLU
- Development stage
- Preclinical
- Lead developer
- PharmaPlanter Technologies
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
NASAL-PPGV-FLU is a preclinical-stage mucosal vaccine candidate developed by PharmaPlanter Technologies. It utilizes a Gas Vesicle Nanoparticle (GVNP) platform to deliver antigens from SARS-CoV-2 (COVID-19), Influenza A, and Influenza B. Administered intranasally, the vaccine is designed to induce both local mucosal immunity at the site of entry and systemic immune responses. The GVNP technology serves as a self-adjuvanting delivery vehicle that presents viral antigens to the immune system, potentially offering broad protection against respiratory viral infections.
- Other names
- PPGV-FLUGas Vesicle Nanoparticle mucosal vaccine
Beyond the preview
Go deeper on NASAL-PPGV-FLU.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NASAL-PPGV-FLU.